Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Stratifying Patients with Haematuria into High or Low Risk Groups for Bladder Cancer: a Novel Clinical Scoring System

  • Published : 2013.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Haematuria is a common presentation of bladder cancer and requires a full urologic evaluation. This study aimed to develop a scoring system capable of stratifying patients with haematuria into high or low risk groups for having bladder cancer to help clinicians decide which patients need more urgent assessment. This cross-sectional study included all adult patients referred for haematuria and subsequently undergoing full urological evaluation in the years 2001 to 2011. Risk factors with strong association with bladder cancer in the study population were used to design the scoring system. Accuracy was determined by the area under the receiver operating characteristic (ROC) curve. A total of 325 patients with haematuria were included, out of which 70 (21.5%) were diagnosed to have bladder cancer. Significant risk factors associated with bladder cancer were male gender, a history of cigarette smoking and the presence of gross haematuria. A scoring system using 4 clinical parameters as variables was created. The scores ranged between 6 to 14, and a score of 10 and above indicated high risk for having bladder cancer. It was found to have good accuracy with an area under the ROC curve of 80.4%, while the sensitivity and specificity were 90.0% and 55.7%, respectively. The scoring system designed in this study has the potential to help clinicians stratify patients who present with haematuria into high or low r isk for having bladder cancer. This will enable high-risk patients to undergo urologic assessment earlier.

Keywords

References

  1. Alishahi S, Byrne D, Goodman CM, et al (2002). Haematuria investigation based on a standard protocol: emphasis on the diagnosis of urological malignancy. J R Coll Surg Edinb, 47, 422-7.
  2. Buntinx F, Wauters H (1997). The diagnostic value of macroscopic haematuria in diagnosing urological cancers: a meta- analysis. Fam Pract, 14, 63-8. https://doi.org/10.1093/fampra/14.1.63
  3. Cha EK, Tirsar LA, Schwentner C, et al (2012). Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. World J Urol, 30, 847-52. https://doi.org/10.1007/s00345-012-0979-x
  4. Edwards TJ, Dickinson AJ, Natale S, et al (2006). A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int, 97, 301-5. https://doi.org/10.1111/j.1464-410X.2006.05976.x
  5. Gore JL, Lai J, Setodji CM, et al (2009). Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results- Medicare analysis. Cancer, 115, 988-96. https://doi.org/10.1002/cncr.24052
  6. Grossfeld GD, Litwin MS, Wolf JS Jr, et al (2001). Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology, 57, 604-10. https://doi.org/10.1016/S0090-4295(01)00920-7
  7. Grossfeld GD, Litwin MS, Wolf JS, et al (2001). Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology, 57, 599-603. https://doi.org/10.1016/S0090-4295(01)00919-0
  8. Grossman HB, Messing E, Soloway M, et al (2005). Detection of bladder cancer using a point-of-care proteomic assay. JAMA, 293, 810-6. https://doi.org/10.1001/jama.293.7.810
  9. Kelly JD, Fawcett DP, Goldberg LC (2009). Assessment and management of non-visible haematuria in primary care. BMJ, 338, 227-32. https://doi.org/10.1136/bmj.b227
  10. Khadra MH, Pickard RS, Charlton M, et al (2000). A prospective analysis of 1930 patients with hematuria to evaluate current diagnostic practice. J Urol, 163, 524-7. https://doi.org/10.1016/S0022-5347(05)67916-5
  11. Lotan Y, Capitanio U, Shariat SF, et al (2009). Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int, 103, 1368-74. https://doi.org/10.1111/j.1464-410X.2009.08360.x
  12. Madeb R, Messing EM (2008). Long-term outcome of home dipstick testing for hematuria. World J Urol, 26, 19-24. https://doi.org/10.1007/s00345-007-0224-1
  13. Messing E (2007). Markers of detection. Urol Oncol, 25, 344-7. https://doi.org/10.1016/j.urolonc.2007.05.012
  14. Messing EM, Young TB, Hunt VB, et al (1987). The signiWcance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol, 137, 919-22. https://doi.org/10.1016/S0022-5347(17)44294-7
  15. Summerton N, Mann S, Rigby AS, et al (2002). Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies. Br J Gen Pract, 52, 284-9.
  16. Wallace DMA, Bryan RT, Dunn JA, et al (2002). Delay and survival in bladder cancer. BJU Int, 89, 868-78. https://doi.org/10.1046/j.1464-410X.2002.02776.x

Cited by

  1. Identification of Patients with Microscopic Hematuria who are at Greater Risk for the Presence of Bladder Tumors Using a Dedicated Questionnaire and Point of Care Urine Test - A Study by the Members of Association of Urooncology, Turkey vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6283
  2. External Validation of a Clinical Scoring System for Hematuria vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6819
  3. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma vol.15, pp.1, 2015, https://doi.org/10.1186/s12894-015-0018-5